FDA seeks feedback on potential regulatory approaches for generative AI-enabled medical devices

The U.S. Food and Drug Administration has released a discussion paper outlining possible regulatory frameworks for generative AI-enabled medical devices and is seeking public comment. The document addresses issues such as risk assessment, premarket evaluation, and post-market monitoring for clinical AI tools that continuously learn, signaling a move toward more structured oversight of advanced AI in patient care.